- Record: found
- Abstract: found
- Article: found
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Lisa A Jackson
1 ,
Alejandra Gurtman ,
Martin van Cleeff ,
Kathrin U Jansen ,
Deepthi Jayawardene ,
Carmel Devlin ,
Daniel A Scott ,
Emilio A Emini ,
William C Gruber ,
Beate Schmoele-Thoma
Aug 2 2013
13-valent pneumococcal conjugate vaccine,
23-valent polysaccharide vaccine,
7-valent pneumococcal conjugate vaccine,
AE,
Adult,
CI,
CRM197,
GMR,
GMT,
IPD,
LLOQ,
LOD,
OPA,
PCV,
PCV13,
PCV7,
PPSV23,
Pneumococcal conjugate vaccine,
Pneumonia,
RCDC,
SAE,
adverse event,
confidence interval,
cross-reactive material 197,
geometric mean ratio,
geometric mean titer,
invasive pneumococcal disease,
limit of detection,
lower limit of quantitation,
opsonophagocytic activity,
pneumococcal polysaccharide conjugate vaccine,
reverse cumulative distribution curve,
serious adverse event
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are efficacious against pneumococcal disease in children and may also offer advantages in adults.
Related collections
Author and article information
13-valent pneumococcal conjugate vaccine,23-valent polysaccharide vaccine,7-valent pneumococcal conjugate vaccine,AE,Adult,CI,CRM197,GMR,GMT,IPD,LLOQ,LOD,OPA,PCV,PCV13,PCV7,PPSV23,Pneumococcal conjugate vaccine,Pneumonia,RCDC,SAE,adverse event,confidence interval,cross-reactive material 197,geometric mean ratio,geometric mean titer,invasive pneumococcal disease,limit of detection,lower limit of quantitation,opsonophagocytic activity,pneumococcal polysaccharide conjugate vaccine,reverse cumulative distribution curve,serious adverse event
13-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine, 7-valent pneumococcal conjugate vaccine, AE, Adult, CI, CRM197, GMR, GMT, IPD, LLOQ, LOD, OPA, PCV, PCV13, PCV7, PPSV23, Pneumococcal conjugate vaccine, Pneumonia, RCDC, SAE, adverse event, confidence interval, cross-reactive material 197, geometric mean ratio, geometric mean titer, invasive pneumococcal disease, limit of detection, lower limit of quantitation, opsonophagocytic activity, pneumococcal polysaccharide conjugate vaccine, reverse cumulative distribution curve, serious adverse event